We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines
Read MoreHide Full Article
Ionis Pharmaceuticals, Inc. (IONS - Free Report) announced that it has entered into a collaboration with a California-based privately-held gene editing company, Metagenomi, to add gene editing to its broad technology platform.
With this partnership, the companies are looking to leverage Ionis' expertise in RNA-targeted therapeutics with Metagenomi's next-generation gene editing systems to develop novel genetic targets.
Initially, the companies will jointly research and develop investigational medicines for up to four genetic targets, with IONS reserving the right to add four additional targets upon achieving certain pre-determined development milestones.
Per the agreement, Ionis will make an upfront payment of $80 million to Metagenomi along with potential future milestone payments and royalties
The collaboration looks like a good strategic fit for Ionis as it is likely to help the company to diversify its broad technology platform of RNA-targeted therapeutics and deliver precision genetic medicines with gene-editing technology.
Shares of Ionis have rallied 44.8% so far this year against the industry’s decline of 29.5%.
Image Source: Zacks Investment Research
We note that Ionis’ RNA antisense technology has allowed the company to form an impressive set of partnerships with leading drugmakers for the development and marketing of its drugs.
Ionis earns commercial revenues, primarily royalty payments on net sales of Biogen's Spinraza and R&D revenues from partnered medicines.
Biogen is responsible for commercializing Spinraza, which is approved for treating spinal muscular atrophy worldwide. Ionis receives royalties from BIIB on Spinraza’s sales. The companies are also developing several other candidates, including tofersen for treating SOD1-ALS (amyotrophic lateral sclerosis) and other neurological diseases.
Meanwhile, AstraZeneca and Novartis are Ionis’ partners for pipeline candidates eplontersen and pelacarsen.
Ionis and AZN will file a new drug application seeking approval of eplontersen for TTR polyneuropathy later in 2022. Ionis and AstraZeneca are also developing eplontersen for the treatment of cardiomyopathy in the phase III CARDIO-TTRansform study.
Ionis and Novartis are evaluating pelacarsen in the ongoing phase III cardiovascular outcome study, HORIZON, in patients with established cardiovascular disease and elevated lipoprotein(a), or Lp(a).
Image: Bigstock
Ionis (IONS) Inks Deal to Develop Precision Genetic Medicines
Ionis Pharmaceuticals, Inc. (IONS - Free Report) announced that it has entered into a collaboration with a California-based privately-held gene editing company, Metagenomi, to add gene editing to its broad technology platform.
With this partnership, the companies are looking to leverage Ionis' expertise in RNA-targeted therapeutics with Metagenomi's next-generation gene editing systems to develop novel genetic targets.
Initially, the companies will jointly research and develop investigational medicines for up to four genetic targets, with IONS reserving the right to add four additional targets upon achieving certain pre-determined development milestones.
Per the agreement, Ionis will make an upfront payment of $80 million to Metagenomi along with potential future milestone payments and royalties
The collaboration looks like a good strategic fit for Ionis as it is likely to help the company to diversify its broad technology platform of RNA-targeted therapeutics and deliver precision genetic medicines with gene-editing technology.
Shares of Ionis have rallied 44.8% so far this year against the industry’s decline of 29.5%.
Image Source: Zacks Investment Research
We note that Ionis’ RNA antisense technology has allowed the company to form an impressive set of partnerships with leading drugmakers for the development and marketing of its drugs.
Ionis has collaboration deals with pharma giants such as Biogen (BIIB - Free Report) , AstraZeneca (AZN - Free Report) and Novartis (NVS - Free Report) .
Ionis earns commercial revenues, primarily royalty payments on net sales of Biogen's Spinraza and R&D revenues from partnered medicines.
Biogen is responsible for commercializing Spinraza, which is approved for treating spinal muscular atrophy worldwide. Ionis receives royalties from BIIB on Spinraza’s sales. The companies are also developing several other candidates, including tofersen for treating SOD1-ALS (amyotrophic lateral sclerosis) and other neurological diseases.
Meanwhile, AstraZeneca and Novartis are Ionis’ partners for pipeline candidates eplontersen and pelacarsen.
Ionis and AZN will file a new drug application seeking approval of eplontersen for TTR polyneuropathy later in 2022. Ionis and AstraZeneca are also developing eplontersen for the treatment of cardiomyopathy in the phase III CARDIO-TTRansform study.
Ionis and Novartis are evaluating pelacarsen in the ongoing phase III cardiovascular outcome study, HORIZON, in patients with established cardiovascular disease and elevated lipoprotein(a), or Lp(a).
Zacks Rank
Ionis currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.